Trial Profile
A phase II study of erlotinib and predictive markers as first-line treatment of advanced non-small cell lung cancer for patients unfit for chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Jul 2014 Planned End Date changed from 1 Dec 2010 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 23 Mar 2011 Planned end date (December 2010) added as reported by ClinicalTrials.gov.